BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fujita H, Sueyoshi S, Tanaka T, Tanaka Y, Sasahara H, Shirouzu K, Suzuki G, Hayabuchi N, Inutsuka H. Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers. J Surg Oncol. 2005;90:209-219. [PMID: 15906363 DOI: 10.1002/jso.20259] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang T, Guo Z, Chen X, Dong J, Jiang H, Tang P, Wang P, Qian D, Zhang W, Pang Q. A retrospective study comparing definitive chemoradiotherapy vs. chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy. Radiat Oncol 2022;17:148. [PMID: 35999608 DOI: 10.1186/s13014-022-02116-0] [Reference Citation Analysis]
2 Li J, Ma S. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer. Thorac Cancer 2021;12:2293-9. [PMID: 34254738 DOI: 10.1111/1759-7714.14069] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Lo CM, Wang YM, Chen YH, Fang FM, Huang SC, Lu HI, Li SH. The Impact of Radiotherapy Dose in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. Curr Oncol 2021;28:1354-65. [PMID: 33805318 DOI: 10.3390/curroncol28020129] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Hassen HY, Teka MA, Addisse A. Survival Status of Esophageal Cancer Patients and its Determinants in Ethiopia: A Facility Based Retrospective Cohort Study. Front Oncol 2020;10:594342. [PMID: 33659206 DOI: 10.3389/fonc.2020.594342] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Huang TT, Li SH, Chen YH, Lu HI, Lo CM, Fang FM, Chou SY, Chiu YC, Chou YP, Wang YM. Definitive chemoradiotherapy for clinical T4b esophageal cancer - Treatment outcomes, failure patterns, and prognostic factors. Radiother Oncol 2021;157:56-62. [PMID: 33482233 DOI: 10.1016/j.radonc.2021.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Suzuki T, Okamura A, Watanabe M, Mine S, Imamura Y, Asari T, Osumi H, Nakayama I, Ichimura T, Ogura M, Ooki A, Takahari D, Yamaguchi K, Chin K. Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2020;27:1510-7. [DOI: 10.1245/s10434-019-08124-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Okamura A, Hayami M, Kozuki R, Takahashi K, Toihata T, Imamura Y, Mine S, Watanabe M. Salvage esophagectomy for initially unresectable locally advanced T4 esophageal squamous cell carcinoma. Esophagus. 2020;17:59-66. [PMID: 31595397 DOI: 10.1007/s10388-019-00700-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
8 Mattiucci GC, Cellini F. Role of the modern radiotherapy in the postoperative setting for esophageal cancer. J Thorac Dis 2017;9:4212-5. [PMID: 29268474 DOI: 10.21037/jtd.2017.10.07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 So B, Marcu L, Olver I, Gowda R, Bezak E. Oesophageal cancer: Which treatment is the easiest to swallow? A review of combined modality treatments for resectable carcinomas. Crit Rev Oncol Hematol 2017;113:135-50. [PMID: 28427503 DOI: 10.1016/j.critrevonc.2017.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
10 Tanaka Y, Yoshida K, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. Cancer Sci 2016;107:764-72. [PMID: 27061001 DOI: 10.1111/cas.12943] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
11 Tanaka Y, Yoshida K, Yamada A, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K, Miyazaki T. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2016;77:1143-52. [PMID: 26896963 DOI: 10.1007/s00280-016-2985-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
12 Akutsu Y, Matsubara H. Chemoradiotherapy and surgery for T4 esophageal cancer in Japan. Surg Today. 2015;45:1360-1365. [PMID: 25583206 DOI: 10.1007/s00595-015-1116-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
13 Cong Z, Diao Q, Yi J, Xiong L, Wu H, Qin T, Jing H, Li D, Shen Y. Esophagectomy Combined With Aortic Segment Replacement for Esophageal Cancer Invading the Aorta. The Annals of Thoracic Surgery 2014;97:460-6. [DOI: 10.1016/j.athoracsur.2013.10.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Fujita H. President's address of the 65th annual scientific meeting of the Japanese Association for Thoracic Surgery: challenges for advanced esophageal cancer. Gen Thorac Cardiovasc Surg 2013;61:201-7. [PMID: 23404311 DOI: 10.1007/s11748-013-0213-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Bharat A, Crabtree T. Management of advanced-stage operable esophageal cancer. Surg Clin North Am 2012;92:1179-97. [PMID: 23026277 DOI: 10.1016/j.suc.2012.07.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
16 Usui A, Akutsu Y, Kano M, Shuto K, Sakata H, Yoneyama Y, Ikeda N, Oide T, Matsubara H. Diffusely infiltrative squamous cell carcinoma of the esophagus presenting as a case with diagnostic difficulty. Surg Today 2013;43:794-9. [PMID: 23124707 DOI: 10.1007/s00595-012-0400-9] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
17 Tomblyn MB, Goldman BH, Thomas CR Jr, Benedetti JK, Lenz HJ, Mehta V, Beeker T, Gold PJ, Abbruzzese JL, Blanke CD; SWOG GI Committee. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac Oncol 2012;7:906-12. [PMID: 22481235 DOI: 10.1097/JTO.0b013e31824c7bed] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
18 Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF, Yasuda T, Yano M, Shiozaki H, Mori M, Doki Y. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology 2011;80:307-13. [PMID: 21778771 DOI: 10.1159/000329806] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
19 Buchmann I, Haberkorn U, Schmidtmann I, Brochhausen C, Buchholz HG, Bartenstein P, Hansen T. Influence of cell proportions and proliferation rates on FDG uptake in squamous-cell esophageal carcinoma: a PET study. Cancer Biother Radiopharm 2008;23:172-80. [PMID: 18454686 DOI: 10.1089/cbr.2007.349] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
20 Seto Y, Chin K, Gomi K, Kozuka T, Fukuda T, Yamada K, Matsubara T, Tokunaga M, Kato Y, Yafune A, Yamaguchi T. Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci 2007;98:937-42. [PMID: 17441965 DOI: 10.1111/j.1349-7006.2007.00479.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
21 de Manzoni G, Pedrazzani C, Pasini F, Bernini M, Minicozzi AM, Giacopuzzi S, Grandinetti A, Cordiano C. Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol. 2007;95:261-266. [PMID: 17323341 DOI: 10.1002/jso.20640] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
22 Vrouenraets BC, van Lanschot JJB. Extent of Surgical Resection for Esophageal and Gastroesophageal Junction Adenocarcinomas. Surgical Oncology Clinics of North America 2006;15:781-91. [DOI: 10.1016/j.soc.2006.07.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
23 Motoyama S, Sugiyama T, Ueno Y, Okamoto H, Takasawa S, Nanjo H, Watanabe H, Maruyama K, Okuyama M, Ogawa J. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy. Ann Surg Oncol. 2006;13:1724-1731. [PMID: 17009160 DOI: 10.1245/s10434-006-9075-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
24 Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival After Neoadjuvant Therapy Compared with Surgery Alone for Resectable Esophageal Cancer in a Population-based Study. World J Surg 2006;30:2182-90. [DOI: 10.1007/s00268-006-0016-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
25 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]